Back to Search Start Over

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial

Authors :
John R. Ingram
H K Bell
Gudula Kirtschig
B Walker
Fiona Antony
M Walsh
Eva-B. Bröcker
Ingrid Salvary
J Wee
Emilia Duarte-Williamson
H Santander
Kathy Taghipour
David Gawkrodger
Enno Schmidt
Sam Gibbs
Alison M Layton
Michael Sticherling
J Adams
M Vatve
Joanne R Chalmers
Hywel C Williams
Fiona Craig
S Blackford
A Carmichael
Walter Bottomley
Adzura Azam
Chris Lovell
Karen E. Harman
Margaret Childs
Alexander Vincent Anstey
K. Hussain
Marinella Nik
C Günthert
A. Chapman
N. van Beek
Andrew M Wright
Rainer Hügel
C Barnard
Indre Verpetinske
K Davies
Thomas A. Luger
A Omerod
Karen Gibbon
Alex Waters
V Akhras
Robert Charles-Holmes
Shyamal Wahie
John C. English
James Mason
R.R. Coelho
Girish Khandubhai Patel
Robert Ellis
Jane C. Sterling
A Lloyd Lavery
Thomas R. Godec
Fenella Wojnarowska
Jane Ravenscroft
Richard Groves
H Malhomme
Kerstin Steinbrink
Andrew J. Nunn
Regine Gläser
Emma Veysey
Adam Ferguson
V Lewis
Diane Whitham
V Venning
M Westmoreland
G Wong
Chris Bower
N. Hepburn
C Thomas
P J Hampton
R. Wachsmuth
Andrew Ilchyshyn
Nick J. Levell
M G S Dunnill
S. Walton
R Rallan
Source :
Lancet (London, England)
Publication Year :
2017
Publisher :
Elsevier, 2017.

Abstract

BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids. METHODS: We did a pragmatic, multicentre, parallel-group randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (

Details

Language :
English
ISSN :
1474547X and 01406736
Volume :
389
Issue :
10079
Database :
OpenAIRE
Journal :
Lancet (London, England)
Accession number :
edsair.doi.dedup.....2f5e1678ec8864f4fa72ceb86b309227